Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Naloxone partly counteracts apomorphine side effects.

U Bonuccelli1, P Piccini, P Del Dotto

  • 1Institute of Neurology, University of Pisa, Italy.

Clinical Neuropharmacology
|October 1, 1991
PubMed
Summary

Naloxone, an opioid antagonist, effectively reduced side effects like sleepiness and nausea caused by apomorphine in Parkinson

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis.

Thyroid : official journal of the American Thyroid Association·2000
Same author

Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study.

Acta neurologica Scandinavica·2000
Same author

Prevalence of headache syndromes in panic disorder.

International clinical psychopharmacology·1999
Same author

Psychiatric comorbidity and psychosocial stress in patients with tension-type headache from headache centers in Italy. The Italian Collaborative Group for the Study of Psychopathological Factors in Primary Headaches.

Cephalalgia : an international journal of headache·1999
Same author

T-cell interleukin-6 receptor binding in patients with myasthenia gravis.

Journal of the neurological sciences·1998
Same author

Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases.

The Journal of clinical endocrinology and metabolism·1997

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Parkinsonian syndrome is characterized by motor and non-motor symptoms.
  • Apomorphine is a dopamine agonist used to manage Parkinson's disease symptoms.
  • Apomorphine administration can provoke acute side effects.

Purpose of the Study:

  • To investigate the efficacy of naloxone in mitigating apomorphine-induced side effects.
  • To assess the role of opioid antagonism in managing dopaminergic drug adverse effects.

Main Methods:

  • A double-blind study involving patients with Parkinson's disease and parkinsonism.
  • Administration of apomorphine to test dopaminergic responsiveness.
  • Infusion of saline or naloxone prior to apomorphine administration.

Main Results:

Related Experiment Videos

  • Naloxone significantly delayed the onset of sleepiness.
  • Naloxone reduced the intensity of yawning, sleepiness, nausea, and vomiting.
  • Opioid antagonism demonstrated a protective effect against acute apomorphine side effects.

Conclusions:

  • Naloxone shows potential in preventing acute side effects associated with apomorphine.
  • Opioid antagonists may be beneficial in managing adverse reactions to dopaminergic agents.
  • Further research into naloxone's role in Parkinson's disease management is warranted.